[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai MicroPort EP MedTech Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,71,92,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100599078","clinical-study-on-the-efficiency-of-rapid-arrhythmia-mapping-using-easystars-high-density-mapping-catheter-applications-100599078",false,"NCT07079813","Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","Rapid Arrhythm","1. Clinical diagnosis: Ventricular tachycardia (VT)\n\n   * Inclusion criteria:\n\n     1. Patients aged between 18 and 80 years;\n     2. Confirmed diagnosis of ventricular tachycardia (VT) via electrocardiogram (ECG) or 24-hour Holter monitoring;\n     3. The patient has experienced at least one episode of VT in the past 6 months and exhibits symptoms of sustained or paroxysmal ventricular tachycardia;\n     4. The patient meets the criteria for ablation surgery and has clear indications for ablation;\n     5. The patient is in good general health and able to tolerate surgery (no severe underlying heart disease, such as severe heart failure or severe coronary artery disease);\n     6. Voluntarily participates and signs an informed consent form.\n   * Exclusion criteria:\n\n     1. Uncontrolled heart failure (New York Heart Association functional class III-IV);\n     2. History of acute or progressive myocardial infarction;\n     3. Severe pulmonary, hepatic, or renal disease;\n     4. Valvular heart disease or congenital heart disease;\n     5. Excessive use of medications or medication intolerance (e.g., beta-blockers, antiarrhythmic drugs);\n2. Clinical diagnosis: Atrial tachycardia (AT)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with atrial tachycardia (AT) by electrocardiogram (ECG) or Holter monitoring;\n     3. Patients presenting with clinical symptoms such as palpitations, chest tightness, or fatigue;\n     4. Patients diagnosed with persistent or paroxysmal atrial tachycardia and meeting the criteria for ablation therapy;\n     5. Patients who voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease or congenital heart disease;\n     2. Patients with severe left ventricular or right ventricular heart failure;\n     3. Patients with severe systemic diseases, such as liver failure, kidney failure, or tumours;\n     4. Patients with cardiomyopathy or aortic dissection;\n3. Clinical diagnosis: atypical atrial flutter (AFL)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Patients diagnosed with atypical atrial flutter (AFL) via electrocardiogram (ECG) or Holter monitoring;\n     3. Patients with clinical symptoms (e.g., palpitations, chest tightness, fatigue, etc.) that significantly impair their quality of life;\n     4. Patients who meet the criteria for atrial tachycardia ablation and have no other severe comorbidities;\n     5. Voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe heart disease, such as cardiomyopathy or severe valvular disease;\n     2. Patients with severe pulmonary disease, such as pulmonary arterial hypertension;\n     3. Patients with a history of major cardiac surgery (e.g., heart transplantation);\n4. Clinically diagnosed with paroxysmal atrial fibrillation (PAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with paroxysmal atrial fibrillation (PAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Frequent episodes of paroxysmal atrial fibrillation with symptoms such as palpitations, fatigue, and dyspnoea, and meeting the criteria for ablation;\n     4. No other severe cardiac or systemic diseases, and meeting the criteria for ablation;\n     5. Voluntarily participating and signing the informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease, aortic dissection, or cardiomyopathy;\n     2. High-risk patients with a history of anticoagulant therapy or currently receiving anticoagulant therapy (e.g., history of thrombosis or stroke);\n     3. Patients with severe underlying conditions such as cancer or severe diabetes;\n5. Clinical diagnosis: Persistent atrial fibrillation (PsAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with persistent atrial fibrillation (PsAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Atrial fibrillation persisting for more than 7 days and symptoms affecting the patient's quality of life;\n     4. Clear indications for ablation and no other severe comorbidities;\n     5. Voluntarily participating and signing an informed consent form.\n\nExclusion criteria:\n\n1. Presence of severe valvular heart disease or cardiomyopathy;\n2. History of stroke or clinical evidence of thrombus formation;\n3. Severe heart failure (NYHA III-IV class);\n4. High-risk cardiac conditions (e.g., acute myocardial infarction, coronary artery disease); In the above different types of rapid arrhythmias, the inclusion criteria primarily focus on the diagnosis and control of clinical symptoms for different types of arrhythmias, while the exclusion criteria focus on avoiding patients with severe comorbidities or those unable to tolerate surgery. Through this patient screening method, the safety of the study and the accuracy of the data are ensured, thereby enabling a better assessment of the clinical efficacy of the new EasyStars catheter.","ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.",[27,28,29,30],"Ventricular Tachycardia (VT)","Atrial Tachycardia","Typical Atrial Flutter","Paroxysmal Atrial Fibrillation (PAF)","NOT_YET_RECRUITING","2025-07-28",{"date":34,"type":35},"2025-07-31","ACTUAL",{"date":37,"type":21},"2025-08-30",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Shanghai MicroPort EP MedTech Co., Ltd.","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100598121","clinical-study-on-the-safety-and-efficacy-of-a-new-magnetic-navigation-radiofrequency-ablation-catheter-for-rapid-arrhythmia-100598121","NCT07067372","Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhythmia","Clinical Study on the Safety and Efficacy of FireMagic™ Magbot Ablation Catheter for Rapid Arrhythmia","Rapid arrhythm","Inclusion Criteria:\n\n* 1\\) Patients aged 18 to 80 years old, with no gender restrictions; 2) Patients clinically diagnosed with paroxysmal atrial fibrillation or symptomatic supraventricular tachycardia: i. For patients with paroxysmal atrial fibrillation, atrial fibrillation was recorded by surface electrocardiogram or Holter monitoring (including single-lead electrocardiogram) within one year prior to enrolment; ii. For patients with symptomatic supraventricular tachycardia, PSVT (AVNRT or AVRT) was recorded by electrocardiogram, Holter monitoring, or electrophysiological examination; 3) Patients who have not responded adequately to or are intolerant of at least one antiarrhythmic drug, or who are willing to undergo ablation surgery without prior medication; 4) Patients who fully understand the treatment plan, voluntarily sign the informed consent form, and are willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n* 1\\) Left atrial thrombus (not applicable for PSVT); 2) Left atrial anteroposterior diameter ≥55 mm (not applicable for PSVT); 3) Left ventricular ejection fraction (LVEF) ≤40%; 4) Previous history of atrial septal defect repair or atrial myxoma (not applicable for PSVT); 5) Presence of active implantable devices (e.g., pacemaker, ICD, etc.); 6) NYHA functional class III-IV; 7) History of cerebrovascular disease within the past 6 months (including cerebral haemorrhage, stroke, transient ischaemic attack); 8) History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, atrial or ventricular incision); 9) Acute or severe systemic infection; 10) Patients with severe liver or kidney disease, malignant tumours, or end-stage diseases, or those whom the investigator believes may interfere with the treatment, evaluation, or compliance of this trial; 11) Patients with a significant tendency to bleed, hypercoagulable states, or severe haematological disorders.",{"count":52,"type":21},20,[24],"Clinical study on the safety and efficacy of FireMagic™ Magbot Ablation Catheter for rapid arrhythmia",[56,57,58],"Rapid Arrhythmia","PFA","Symptomatic Supraventricular Tachycardia",[60,61],"Paroxysmal atrial fibrillation","Symptomatic supraventricular tachycardia","2025-07-14",{"date":64,"type":35},"2025-07-16",{"date":66,"type":21},"2025-12-31",{"date":68,"type":21},"2028-12-31",{"name":41,"class":42},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":70},"100595944","a-clinical-study-on-the-use-of-a-domestically-produced-three-dimensional-cardiac-electrophysiological-mapping-system-combined-with-pressure-monitoring-technology-and-star-mapping-technology-for-the-treatment-of-paroxysmal-atrial-fibrillation-100595944","NCT07039032","A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.","paroxysmal at","Inclusion Criteria:\n\n1. Patient age between 18 and 80 years old, male or non-pregnant female.\n2. Confirmed diagnosis of paroxysmal atrial fibrillation requiring catheter radiofrequency ablation surgery.\n3. Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n1. Post-ablation for atrial fibrillation\n2. Reproductive-age patients who cannot use effective contraception within 12 months of enrolment\n3. Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%\n4. Left atrial thrombus\n5. History of atrial septal defect repair or atrial myxoma\n6. History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)\n7. History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)\n8. Patients with acute or severe systemic infection\n9. Patients with severe liver or kidney disease\n10. Patients with significant bleeding tendencies or haematological disorders\n11. Patients with malignant tumours or end-stage diseases\n12. Patients deemed ineligible for this trial by the investigator",{"count":52,"type":21},[24],"Validating the safety and efficacy of pressure monitoring technology and star-shaped marking technology for the treatment of paroxysmal atrial fibrillation",[30],[57,83,84],"PeAF","PFA\u002FRF","2025-06-26",{"date":87,"type":35},"2025-06-27",{"date":89,"type":21},"2025-09-30",{"date":68,"type":21},{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":70},"100595716","a-clinical-study-on-the-use-of-a-domestically-produced-cryoablation-system-combined-with-balloon-cryoablation-technology-for-the-treatment-of-paroxysmal-atrial-fibrillation-100595716","NCT07036068","A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology for the Treatment of Paroxysmal Atrial Fibrillation","Balloon cryoab","Inclusion Criteria:\n\n1. Patient age between 18 and 80 years old, male or non-pregnant female.\n2. Confirmed diagnosis of paroxysmal atrial fibrillation requiring cryoablation surgery.\n3. Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n1. Patients who have undergone atrial fibrillation ablation surgery\n2. Reproductive-age patients who cannot use effective contraception within 12 months of enrolment\n3. Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%\n4. Left atrial thrombus\n5. Patients who have undergone atrial septal defect repair surgery or atrial myxoma\n6. Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)\n7. Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)\n8. Patients with acute or severe systemic infection\n9. Patients with severe liver or kidney disease\n10. Patients with a significant tendency to bleed or haematological disorders\n11. Patients with malignant tumours or end-stage diseases\n12. Patients deemed ineligible for this trial by the investigator",{"count":52,"type":21},[24],"To validate the safety and efficacy of balloon cryoablation technology and the accompanying disposable intracardiac mapping electrode catheter and adjustable guide sheath for the treatment of paroxysmal atrial fibrillation.",[30],[57,83,84],{"date":87,"type":35},{"date":106,"type":21},"2025-08-31",{"date":39,"type":21},{"name":41,"class":42},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":127,"locationsCount":4},"100595476","safety-and-efficacy-study-of-the-first-domestically-produced-firemagic-precisense-3d-microelectrode-ablation-catheter-therapy-for-rapid-arrhythmia-with-tissue-temperature-measurement-function-100595476","NCT07032948","Safety and Efficacy Study of the First Domestically Produced FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter Therapy for Rapid Arrhythmia With Tissue Temperature Measurement Function","1\\. Inclusion Criteria\n\n1. Patient age between 18 and 75 years old, male or non-pregnant female;\n2. Confirmed diagnosis of supraventricular tachycardia or atrial fibrillation requiring catheter radiofrequency ablation surgery;\n3. Signed informed consent form approved by the ethics committee;\n4. Willingness to undergo follow-up and evaluation as required by the protocol.\n\n2\\. Exclusion Criteria Include:\n\n1. Exclusion criteria for atrial fibrillation patients:\n\n   Patients should not participate in this study if any of the following conditions apply:\n   * Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%;\n   * Left atrial thrombus;\n   * History of atrial septal repair or atrial myxoma;\n   * History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack);\n   * Cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision);\n   * Acute or severe systemic infection;\n   * Severe liver or kidney disease;\n   * Significant bleeding tendency or haematological disorders;\n   * Patients with other conditions deemed inappropriate for participation in this trial by the investigators.\n2. Exclusion criteria for patients with ventricular tachycardia and supraventricular tachycardia:\n\nPatients should not participate in this study if any of the following conditions apply:\n\n* Left atrial size ≥50 mm and left ventricular ejection fraction ≤40%;\n* History of atrial septal defect repair or atrial myxoma;\n* Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack);\n* Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision);\n* Patients with acute or severe systemic infection;\n* Patients with severe liver or kidney disease;\n* Patients with a significant tendency to bleed or haematological disorders;\n* Patients with other conditions deemed by the investigator to be unsuitable for participation in this trial.","75 Years",{"count":20,"type":21},[24],"This project aims to evaluate the safety, efficacy, and cost-effectiveness of using FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter to treat rapid arrhythmias.",[56,120,121],"Atrial Fibrillation (AF)","Paroxysmal Supraventricular Tachycardia (PSVT)","2025-06-23",{"date":124,"type":35},"2025-06-24",{"date":106,"type":21},{"date":106,"type":21},{"name":41,"class":42},""]